Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777.
Supporting Patients with aRCC during treatment with cabozantinib + nivolumab
Renal Cell Carcinoma
Video
04:28
Hear from Prof. Laurence Albiges and Prof. James Larkin on the importance of cabo+nivo for the treatment of aRCC.
CBZ-UK-000345 | November 2024
